potential new treatment for this disease. By high-throughput chemical screening of small molecule libraries, Haber and her colleagues have also developed novel MRP1 inhibitors and patented and licensed the compounds for the treatment of neuroblastoma and other MRP1-associated malignancies. This led to a $3.1M award from the Australian Cancer Research Foundation to establish a Drug Discovery Centre for Childhood Cancer in the UNSW Lowy Cancer Research Centre, which is currently developing a pipeline of potential new drugs for treating childhood and adult malignancies. Haber and her collaborators have also identified the role of ATP-binding cassette transporter genes (ABC transporters) in neuroblastoma biology, demonstrating that their expression predicts for poor clinical outcome in neuroblastoma but, unexpectedly, this phenomenon was not due to the ABC proteins’ role in drug transport, but through an independent pathway that influences fundamental aspects of tumour biology. A further study on ovarian cancer and ABCA1 has extended the discovery to common adult cancers. Service to the scientific community Haber is a long-term member of the International Neuroblastoma Risk Group Committee, which makes recommendations regarding standardised protocols and best practice for identifying/utilising prognostic indicators for neuroblastoma treatment risk assessment. From 2006 to 2014, Haber has served on the steering committee of the Advances in Neuroblastoma Research Association (ANRA), the peak international body for neuroblastoma research and was President of this organisation from 2010 to 2012. In 2011, Haber also played a key role in establishment of the Kids Cancer Alliance and currently serves on this organization's executive management committee. Haber is convenor of the 2016 Advances in Neuroblastoma Research conference (Cairns, Australia), one of the largest specialist childhood cancer conferences internationally. Awards and honours In 2007 Haber was appointed a Member of the Order of Australia (AM) for service to science in the field of childhood cancer, to scientific education, and to the community and she was also named as one of Australia’s 25 ‘True Leaders’ by Financial Review’s Boss Magazine. In 2008, Haber was awarded DSc (Honoris Causa) by University of New South Wales for eminent service to the cancer research community. She has received numerous awards for research excellence, including the NSW Science & Engineering Award for Biomedical Sciences (2011), and in that same year was a New South Wales finalist for Australian of the Year. In 2012, Haber (with her long-time collaborators Norris and Marshall) received the Cancer Institute NSW Premier’s Award for Excellence in